Chairman of TauRx and Dr Emer MacSweeney of Re:Cognition Health to speak at ADI Middle East Conference in Dubai on 8-9 December

Dec 06 - 2013 04:54 PM
Two innovative UK thought leaders in Alzheimer’s disease will be speaking at the upcoming 2nd Middle East and North Africa Conference of Alzheimer's Disease International this weekend.
Read more

In Croatia, three international leaders in Alzheimer’s discuss ongoing clinical trials and global dementia policy ahead of the G8 Dementia Research Summit in London next week

Dec 06 - 2013 04:26 PM
Professor Claude Wischik, Chairman of TauRx Therapeutics, Marc Wortmann, Executive Director of Alzheimer’s Disease International (ADI), and Prof. Ninoslav Mimica, President of Alzheimer Croatia, provide the latest news about ADI’s global dementia policy and the Croatian launch of a global Alzheimer’s Research Study
Read more

Phase 3 clinical studies targeting tau aggregation get underway in Korea

Oct 04 - 2013 05:35 AM
Professor Wischik speaks at annual psychogeriatric conference in Korea
Read more

TauRx achieves milestone in global Phase 3 clinical trials of LMTX™ for Alzheimer's Disease

Sep 19 - 2013 10:33 PM
Over 300 patients now enrolled worldwide in clinical trials for a second?generation tau aggregation inhibitor (TAI) aimed at halting the progression of Alzheimer’s
Read more

In Toronto, Two International Leaders Share One Goal: Slow or Halt the Progression of Alzheimer’s Disease with the Launch of Phase 3 Clinical Trials

Jun 11 - 2013 09:53 PM
Professor Claude Wischik, Executive Chairman of TauRx Therapeutics and Dr. Sharon Cohen, Medical Director of the Toronto Memory Program Announce the Canadian Launch of Pivotal Alzheimer’s Research
Read more